TNFRSF4 and cancer: As summarized by Fu et al., multiple preclinical studies of OX40 or OX40L agonists, either as monotherapies or in combination with other modalities, have shown improved anti-tumor responses, decreased tumor growth, and improved survival in different cancer models [88].